Alnylam Pharmaceuticals, Inc. (BMV:ALNY)

Market Cap	1.09T
Revenue (ttm)	46.43B
Net Income (ttm)	-6.02B
Shares Out	n/a
EPS (ttm)	-46.46
PE Ratio	n/a
Forward PE	75.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45
Average Volume	344
Open	8,380.00
Previous Close	8,560.00
Day's Range	8,380.00 - 8,380.00
52-Week Range	4,900.00 - 8,560.00
Beta	n/a
RSI	76.36
Earnings Date	Nov 6, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ALNY

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD